Q-omics provides the consensus-scored ST20-MTHFS profile across patient tissues and cancer cell-line models. ST20-MTHFS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ST20-MTHFS is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ST20-MTHFS RNA expression shows 14,115 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where ST20-MTHFS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST20-MTHFS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST20-MTHFS survival associations across molecular data types. ST20-MTHFS RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST20-MTHFS RNA expression–survival associations across cancer types. High ST20-MTHFS expression shows unfavorable associations in UVM, CESC, LUAD and LGG, but favorable associations in HNSC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ST20-MTHFS RNA expression.
This table summarizes ST20-MTHFS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ST20-MTHFS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST20-MTHFS shows higher tumor expression in HNSC, KIRC, CHOL, BRCA, STAD and LIHC. The HNSC box plot shows higher ST20-MTHFS RNA expression in tumor versus normal tissue (log2 FC = +0.198, t-test p < 0.001).
This table shows molecular features associated with ST20-MTHFS in patient tissues and cancer cell lines. In patient samples, ST20-MTHFS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
